Search Results
Your search for ,dUe matches 5406 pages
Showing 3301 - 3350Lenalidomide, Bortezomib, and Dexamethasone With or Without Transplantation in Younger Myeloma Patients
In the French phase III IFM 2009 trial reported in The New England Journal of Medicine by Michel Attal, MD, of the Institut Universitaire du Cancer de Toulouse-Oncopole, and colleagues, consolidation treatment with lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (RVD) was...
Combination Therapy With Pembrolizumab in Metastatic Nonsquamous NSCLC
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 10, 2017, pembrolizumab (Keytruda) was granted accelerated...
Selected Novel Agents in Development for Multiple Myeloma
Here are several abstracts selected from the proceedings of the 2016 America Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics for the development for patients with relapsed or refractory multiple myeloma. For full details of these study abstracts, visit...
Targeting the Androgen Receptor in Breast Cancer
One of the most active areas of research in breast cancer involves the targeting of the androgen receptor. Trials underway for androgen receptor antagonists and modulators, alone and in various combinations of available agents and novel therapies, are yielding encouraging early results. At the 2017 ...
Idelalisib Toxicities Appear to Be Immune-Related
Phosphoinositide 3-kinase (PI3K) inhibitors represent a highly active class of drug for the treatment of chronic lymphocytic leukemia (CLL). Idelalisib (Zydelig), a PI3K-delta inhibitor and the first PI3K inhibitor to be approved by the U.S. Food and Drug Administration (FDA) for CLL, has...
Venetoclax Achieves Durable and Deep Remissions in CLL
Preliminary study results suggest that venetoclax (Venclexta) plus rituximab (Rituxan) is a highly active combination in relapsed/refractory chronic lymphocytic leukemia (CLL), achieving durable responses and minimal residual disease negativity in previously treated patients. “The results of our...
Expert Point of View: Manish Shah, MD and Daniel F. Hayes, MD, FACP, FASCO
Manish Shah, MD, Director of Gastrointestinal Oncology at NewYork-Presbyterian and Weill Cornell Medicine, was impressed with the findings of the two subanalyses of CALGB 89803. “The study found a 46% reduction in the risk of recurrence with two servings of tree nuts a week, and that’s more than ...
Making American Research Great Again
In the past 10 years, we have made remarkable advances in how we fight cancer. One of the most powerful new tools in our arsenal is cancer immunotherapy, which reawakens our own immune system to produce stunning results for many suffering from advanced cancer. Immunotherapy saved President Jimmy...
FDA Requests Removal of Oxymorphone Hydrochloride for Risks Related to Abuse
On June 8,the U.S. Food and Drug Administration (FDA) requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated oxymorphone hydrochloride (Opana ER), from the market. After careful consideration, the agency is seeking removal based on its concern that the benefits of the...
European Commission Approves Nivolumab for Previously Treated, Locally Advanced, Unresectable or Metastatic Urothelial Cancer
On June 2, the European Commission (EC) approved nivolumab (Opdivo) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. This makes nivolumab the first immuno-oncology agent approved in the European Union ...
Adjuvant Gefitinib Delays Recurrence in EGFR-Positive NSCLC
Adjuvant therapy with gefitinib (Iressa), an epidermal growth factor receptor (EGFR)-targeted agent, was more successful at preventing recurrence than standard-of-care chemotherapy, in a phase III study of patients with EGFR-positive non–small cell lung cancer (NSCLC).1 Gefitinib extended...
ASCO 2017: Adding PEGPH20 to Standard Treatment in Metastatic Pancreatic Cancer May Delay Disease Progression
By adding an experimental drug to a standard chemotherapy regimen, a subset of patients with metastatic pancreatic cancer had a significantly longer period before the cancer progressed as compared with those who received the standard treatment, according to a phase II clinical trial led by an...
ASCO 2017: Many Emergency Department Visits Among Patients With Cancer Appear Preventable
Among patients with cancer, as many as 53% of emergency department visits that do not require admission could be avoided with better symptom management and greater availability of outpatient care tailored to their needs, according to a new study from Fred Hutchinson Cancer...
ASCO 2017: Research Suggests Possible New Treatment for EGFR-Positive Lung Cancer
Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non–small cell lung cancer (NSCLC). Compared to the EGFR inhibitor gefitinib (Iressa), one of the standard targeted...
OlympiAD Trial: Olaparib in Metastatic Breast Cancer With Germline BRCA Mutation
As reported in the Plenary Session at the 2017 ASCO Annual Meeting and in The New England Journal of Medicine by Robson et al, the phase III OlympiAD trial showed that the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza) prolonged progression-free survival vs standard therapy in...
Xuesong Han, PhD, on Early-Stage Diagnosis and the Affordable Care Act: An Epidemiologic Study
Xuesong Han, PhD, of the American Cancer Society, discusses the Affordable Care Act and her study findings showing how implementation of the law is associated with a shift to early-stage diagnosis for all screenable cancers except prostate cancer (likely due to Task Force recommendations against...
ASCO 2017: OlympiAD Trial: Olaparib Slows Growth of BRCA-Related Metastatic Breast Cancer
Findings from a phase III clinical trial of about 300 women may introduce poly ADP ribose polymerase (PARP) inhibitors as a new type of treatment for breast cancer. Compared to standard chemotherapy, the oral targeted medicine olaparib (Lynparza) reduced the chance of progression of advanced,...
ASCO 2017: Larotrectinib Shows Durable Efficacy Across Diverse Pediatric and Adult Cancers
Scientists may have developed the first targeted, oral, tumor-type agnostic therapy—an agent that works comparably well across many kinds of cancer, regardless of patient age. In clinical trials of adults and children with 17 different types of advanced cancer, larotrectinib treatment...
ASCO 2017: New High-Intensity Genomic Sequencing Approach Detects Circulating Tumor DNA at a High Rate
In a study of 124 patients with advanced breast, lung, and prostate cancers, a new high-intensity genomic sequencing approach detected circulating tumor DNA at a high rate. In 89% of patients, at least one genetic change detected in the tumor was also detected in the blood. Overall, 627 (73%)...
ASCO 2017: Steady Decrease in Severe Health Problems for Childhood Cancer Survivors
Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems...
Celebrating Cancer Survivorship
Sunday, June 4, 2017, marks the 30th anniversary of National Cancer Survivors Day. Here’s a look at the progress that has been made over the past 2 to 3 decades in reducing cancer incidence and cancer deaths and the challenges that remain. Increasing Rates of Cancer Survivorship In 1971, the...
Japanese Phase III Trial of Alectinib vs Crizotinib in ALK-Positive NSCLC
The Japanese phase III J-ALEX trial has shown improved progression-free survival with alectinib (Alecensa) vs crizotinib (Xalkori) in ALK inhibitor–naive patients with ALK-positive non–small-cell lung cancer (NSCLC). Results were reported by Hida et al in The Lancet. Study Details In...
Pembrolizumab in Advanced PD-L1–Positive Endometrial Cancer
Pembrolizumab (Keytruda) showed activity in previously treated patients with advanced programmed cell death ligand 1 (PD-L1)–positive endometrial cancer in a cohort of the phase Ib KEYNOTE-028 study. These findings were reported in the Journal of Clinical Oncology by Ott et al. Study Details ...
FDA Broadens Ceritinib Indication to Previously Untreated ALK-Positive Metastatic NSCLC
On May 26, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to ceritinib (Zykadia) for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. In April 2014,...
Waun Ki Hong, MD, FACP, Helped Change the Standard of Care in Laryngeal Cancer, Now Focuses on Chemoprevention and Precision Medicine
Waun Ki Hong, MD, FACP, one of the nation’s leading experts in head and neck and lung cancers, was born in South Korea and grew up in a tiny village outside the nation’s capital of Seoul. Number six of seven siblings, Dr. Hong described his early life in the cozy village as blissful, until the...
Final Overall Survival Results of TH3RESA Trial in Breast Cancer
The final overall survival results of the phase III TH3RESA trial indicate a 32% reduction in risk of death with ado-trastuzumab emtansine (Kadcyla) vs treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer. The findings were reported in The ...
ASCO President, Bruce E. Johnson, MD, FASCO, Participates in Key Research With EGFR Mutation in Lung Cancer
Bruce E. Johnson, MD, FASCO, 2017–2018 ASCO President, was born in St. Peter, Minnesota, and grew up on a rural dairy farm. “Neither of my parents had college degrees, but working on a dairy farm with them gave me a solid work ethic. I was working outside on the farm before I was 10 years old. In...
OPTIMIZE-2 Trial Offers Reassuring Data on Deescalation of Bisphosphonate Therapy for Breast Cancer–Related Bone Metastases
Bisphosphonates were first synthesized more than a century ago, with their initial usage restricted to a range of industrial processes until their potential clinical relevance was appreciated in the late 1960s.1 Then, following development for the treatment of osteoporosis and Paget’s disease of...
Tackling the Obesity and Cancer Epidemic
Research is still lacking to support a link between obesity and an increased risk of developing all types of cancer. Nevertheless, a review1 of more than 1,000 epidemiologic studies by the International Agency for Research on Cancer (IARC), a division of the World Health Organization, examining...
Unique Challenges Facing Young Women With Breast Cancer
According to the American Cancer Society, over 252,700 new cases of invasive breast cancer will be diagnosed in 2017, and about 40,610 women will die of their disease. Between 7% and 10% of those new cases will be diagnosed in women younger than age 40, accounting for more than 40% of all cancer...
Niraparib in Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
On March 27, 2017, the oral poly ADP-ribose polymerase (PARP) inhibitor niraparib (Zejula) was approved for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.1,2...
Smoldering and Relapsed or Refractory Multiple Myeloma
Here are several abstracts selected from the proceedings of the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in smoldering and relapsed and/or refractory multiple myeloma. For the full details of these study abstracts, visit...
AKT Inhibitor Activity in AKT1-Mutant Solid Tumors
As reported by Hyman et al in the Journal of Clinical Oncology, a basket study has shown activity of an investigational ATP-competitive pan-AKT kinase inhibitor (AZD5363) in solid tumors with AKT1 E17K mutation. Study Details In the study, 52 patients with advanced estrogen...
Final Overall Survival Results of EMILIA Trial in Breast Cancer
As reported in The Lancet Oncology by Diéras et al, the final overall survival results of the phase III EMILIA trial show improved outcome with ado-trastuzumab emtansine (Kadcyla) vs capecitabine plus lapatinib (Tykerb) in previously treated HER2-positive advanced breast cancer. Approval of...
ASCO Issues Recommendations for Reducing Cancer Disparities Among Sexual and Gender Minority Populations
ASCO has issued recommendations addressing the needs of sexual and gender minority populations as they relate to cancer. The recommendations, published in a policy statement in the Journal of Clinical Oncology,1 are designed to focus attention on the challenges facing the sexual and gender...
CheckMate 275 Supports FDA Approval of Nivolumab in Metastatic Urothelial Carcinoma After Platinum Therapy
As reported in The Lancet Oncology by Padmanee Sharma, MD, PhD, of MD Anderson Cancer Center, and colleagues, the phase II CheckMate 275 trial has shown that nivolumab (Opdivo) produced durable responses in patients with metastatic urothelial cancer who had received at least one prior...
The Ongoing Challenges of Lung Cancer Screening
Lung cancer persistently remains the leading cause of cancer death among men and women in the United States. Only about 15% of lung cancers are diagnosed at the localized stage, when clinical intervention could markedly improve patient outcomes. For decades, lung cancer specialists and advocacy...
Atezolizumab Improves Overall Survival in Small Subset of Patients With Triple‑Negative Breast Cancer
Triple-negative breast cancer is an aggressive disease with no approved targeted therapy, and it remains challenging to treat. Early data from a phase I study suggest that the PD-L1 inhibitor atezolizumab (Tecentriq) can extend the lives of a subset of women who respond to this checkpoint...
Abemaciclib Active in Metastatic Breast Cancer
In the single-arm phase II MONARCH 1 trial, the investigational cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib achieved an objective response in about 20% of heavily pretreated patients with metastatic hormone receptor–positive, HER2-negative breast cancer and a disease control rate of...
Managing Small Renal Masses: A Point-by-Point Consideration of ASCO’s Clinical Practice Guideline
As reviewed in this issue of The ASCO Post, a recent issue of the Journal of Clinical Oncology featured an ASCO Clinical Practice Guideline on the management of small renal masses reported by Finelli and colleagues.1 This comprehensive guideline is written by a group of well-regarded and...
ASCO Provisional Clinical Opinion on Hormonal Therapy for Castration-Resistant Prostate Cancer
On April 25, ASCO issued a provisional clinical opinion on the use of second-line hormonal therapy for men with castration-resistant prostate cancer who have not yet received chemotherapy. The recommendations of this provisional clinical opinion were informed by evidence from a systematic review of ...
Rates of Oral HPV Infection Plummet After Vaccination
Vaccination against the human papillomavirus (HPV) reduced the risk of acquiring oral HPV infections by 88%, in one of the first large studies to explore vaccination’s impact in the oropharynx. The study will be presented at the 2017 ASCO Annual Meeting, and the findings were released in advance of ...
The Role of Meditation in Cancer Care
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, authors Shelly Latte-Naor, MD, and Jyothirmai Gubili, MS, present the case...
Expect Questions From Patients Who ‘Do Everything Right’ but Still Develop Cancer
A study reported in Science found that more than two-thirds of human cancers are caused by random mutations made during DNA replication.1 “The main message we would like to convey is that even for many patients who follow all of the guidelines from the advisory bodies—they don’t smoke, exercise...
Recognizing Major Role of Random Mutations in Causing Cancer Does Not Diminish Importance of Primary Prevention
Random mistakes made during DNA replication are responsible for about two-thirds of the mutations that cause human cancers, according to a study reported in Science.1 Recognizing the role of these replication errors “does not diminish the importance of primary prevention but emphasizes that not all ...
Lung Cancer: Hope From Science
The following essay by Paul A. Bunn, Jr, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. I grew up in ...
RECIL 2017: New Response Evaluation Criteria in Lymphoma Clinical Trials
New criteria for evaluating response in lymphoma clinical trials—RECIL 2017—have been developed by an International Working Group with the aim of harmonizing criteria with the Response Evaluation Criteria in Solid Tumors (RECIST). The new criteria were reported by Younes et al in Annals ...
AUA 2017: Studies Highlight Shifts in Prostate Cancer Screening and Management
Active surveillance in men under 60, use of telemedicine in the management of prostate cancer, and physicians' personal prostate cancer screening preferences were all highlighted at the 2017 Annual Scientific Meeting of the American Urological Association (AUA). Active Surveillance for Low-Risk...
ASCO 2017: HPV Vaccination May Reduce Oral HPV Infections but Is Still Underutilized
In one of the first large studies to explore the possible impact of human papillomavirus (HPV) vaccination on oral HPV infections, researchers found it may confer a high degree of protection. The study of young adults in the United States showed that the prevalence of high-risk HPV infection was...
ASCO 2017: Gefitinib Treatment Can Delay Recurrence of Intermediate-Stage Lung Cancer
The targeted therapy gefitinib (Iressa) appears more effective in preventing recurrence after lung cancer surgery than the standard of care, chemotherapy. In a phase III clinical trial, patients with epidermal growth factor receptor (EGFR)-positive, stage II to IIIA non–small cell lung cancer ...
